|
|
Serbia Pharmaceuticals and Healthcare Report Q3 2007Published by: Business Monitor International Published: Nov. 16, 2007 - 70 Pages Table of Contents
AbstractThe Serbian pharmaceutical market, which technically contracted following the June 2006 dissolution ofthe State of Union of Serbia and Montenegro, remains the least developed in Central and Eastern Europe(CEE). However, the country’s desire to join the European Union (EU) will in the longer term boostopportunities for both foreign and domestic stakeholders. In the shorter term, a difficult pricing andreimbursement environment will continue to conspire to hamper market access and development.The relatively underdeveloped status of the primary network has resulted in the dominance of hospitals askey points of care, with prescription medicines consequently accounting for the majority ofpharmaceutical expenditure. Out-of-pocket spend is also high, as state reimbursed medicines are often outof stock and public funds suffer from chronic financial shortages. Generics, on the other hand, representaround one-third of the market in value terms, and a higher percentage in terms of volume. The copysegment will continue to make gains in the forecast period, supported by the need for cost containment aswell as by the suboptimal intellectual property (IP) environment. In the longer term, however, brandedmedicines will benefit from the involvement of foreign players in the domestic industry (throughacquisitions and investment), as well as from the country’s need to align its regulatory environment withthat of the EU. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||